- Pressemitteilung BoxID 61673
The New MagNA Pure LC 2.0 System
New Design and Improved Performance Meet a Proven Nucleic Acid Isolation Technology
The new front door of the MagNA Pure LC 2.0 System requires less space above the instrument; the new surface materials of the stage proved to be resistant to all tested cleaning agents. The new GUI together with the touch screen allows efficient programming and data processing, and the real-time PCR workflow with the Light Cycler® 480 System is improved. The programming of pipetting schemes for various PCR set-ups can easily be done by a separate post-elution software. The error handling of the system has been significantly improved.
The MagNA Pure LC System from Roche Applied Science has been on the market since 1999. This fully automated ("walk-away") system is based on the well-established magnetic bead technology and offers a great variety of applications. The system is designed to automate nucleic acid purification and PCR setup in the medium to high throughput range, flexibly processing 1-32 samples at a time. The duration to purify a full batch of 32 samples is 52-180 minutes, depending on the application. Smaller batches require even shorter run duration. As shown in many publications, the MagNA Pure LC System has proven to be a versatile and reliable tool for isolation of very pure nucleic acids of high integrity (for details on references visit our MagNA Pure Special Interest Site at www.magnapure.com).
Roche Diagnostics GmbH
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
NIMBLEGEN is a trademark of Roche.
Diese Pressemitteilungen könnten Sie auch interessieren
Cannabis als Medizin: Deutsche Schmerzgesellschaft e. V. begrüßt heutigen Beschluss des Deutschen Bundestags zu Cannabis auf Rezept
Schmerzpräsident Prof. Dr. Martin Schmelz: „Ein wichtiger Meilenstein für Patienten und Therapeuten ist erreicht – jetzt kommt es auf eine gute...
Seit Wochen wird Frankreich von einer schweren Grippewelle überrollt, die in Krankenhäusern bereits über 50 Todesopfer gefordert hat. Auch in...
Mit einer Spende in Höhe von insgesamt 15.000 Euro unterstützt QuintilesIMS, einer der weltweit führenden Anbieter von integrierten Informations-...